Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
 BACK TO LIST

European Patient Summary

Patient
Name: Fabbri, , Gioele,
DOB: 12-SEP-1972 (Age: 53)
Gender: male
ID: 3631-767680-1 (ECI)
Author
Dr. Ping, Hel
Patient summary Document
European Patient Summary
Report Date: 10-JUN-2025

Problem list

Condition Onset Date Status
Anemia 22-May-2023 active
Prediabetes 16-May-2022 active
Recurrent rectal polyp 03-Jun-2020 active
Polyp of colon 06-May-2019 active
Hyperlipidemia 22-May-2017 active
Chronic intractable migraine without aura 20-Apr-1993 active

Medication list

Medication Since Form Dosage Reason
Simvastatin 10 mg oral tablet 2025-06-10 - 1 tablet (10 mg) by mouth once daily Hyperlipidemia

Immunizations list

Vaccine Date
Influenza virus antigen only vaccine product 02-Jun-2025
SARS-CoV-2 mRNA vaccine 03-May-2021
Clostridium tetani toxoid antigen adsorbed only vaccine product 04-May-2020
Live attenuated Human alphaherpesvirus 3 only vaccine product 04-May-2020

Procedure History list

Procedure Date Reason
Postoperative care 26-Jun-2020 Overlapping malignant neoplasm of colon
Partial resection of colon 20-Jun-2020 Overlapping malignant neoplasm of colon
Assessment of health and social care needs 24-Sep-2018 -
Assessment of anxiety 24-Sep-2018 -
Assessment using AUDIT-C (Alcohol Use Disorders Identification Test - Consumption) 24-Sep-2018 -
Assessment of substance use 24-Sep-2018 -

Allergies and Intolerances

Allergy/Intolerance Onset Date Status Type Reaction
? active ?

Care Plan

Active Planned Care / Goals Start Date Reason
Diabetes self management plan 16-May-2022 Prediabetes
  • Patient will demonstrate understanding of prediabetes self-management strategies including diet, exercise, and blood glucose monitoring.
  • Maintain hemoglobin A1c below 5.7% to prevent progression to diabetes.
  • Achieve and maintain at least 5% weight loss from baseline to reduce risk of developing diabetes.
  • Engage in at least 150 minutes of moderate-intensity physical activity per week.
Hyperlipidemia clinical management plan 12-Jun-2017 Hyperlipidemia
  • Achieve and maintain LDL cholesterol below 100 mg/dL
  • Achieve and maintain total cholesterol below 200 mg/dL
  • Achieve and maintain triglycerides below 150 mg/dL
  • Achieve and maintain HDL cholesterol above 40 mg/dL

Vital Signs

Vital Signs 2025-06-02 2024-05-27
Body Height 177 cm 177 cm
Pain severity - 0-10 verbal numeric rating [Score] - Reported 3 {score} 3 {score}
Body Weight 87.9 kg 87.9 kg
Body mass index (BMI) [Ratio] 28.1 kg/m2 28.1 kg/m2
Diastolic Blood Pressure 83 mm[Hg] 84 mm[Hg]
Systolic Blood Pressure 125 mm[Hg] 123 mm[Hg]
Heart rate 70 /min 80 /min
Respiratory rate 15 /min 13 /min

Relevant diagnostic tests/laboratory data

Recent Lab Observations 10-JUN-2025 Reference Range Unit
Glucose [Mass/volume] in Blood 77.7 70 - 99 mg/dL
Urea nitrogen [Mass/volume] in Blood 11.5 7 - 20 mg/dL
Creatinine [Mass/volume] in Blood 2.8 H 0.7 - 1.3 mg/dL
Calcium [Mass/volume] in Blood 9.3 8.5 - 10.5 mg/dL
Sodium [Moles/volume] in Blood 138.8 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 4.9 3.5 - 5 mmol/L
Chloride [Moles/volume] in Blood 101.9 98 - 107 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 27.5 24 - 29 mmol/L
Protein [Mass/volume] in Serum or Plasma 6.2 L 6.6 - 8.3 g/dL
Albumin [Mass/volume] in Serum or Plasma 3.8 3.5 - 5.5 g/dL
Globulin [Mass/volume] in Serum by calculation 3.4 2 - 3.5 g/L
Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 0.3 - 1.2 mg/dL
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 65.3 39 - 136 U/L
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 40.7 7 - 52 U/L
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 12.3 10 - 40 U/L
Cholesterol [Mass/volume] in Serum or Plasma 200.4 H 125 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 100.5 0 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 106.5 0 - 130 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 31.4 L 40 - 100 mg/dL

Device Use

Device Date (since)
Blood glucose meter (physical object) 16-May-2022